WO2024080954A1 - Intra-articular gel for tissue and cartilage regeneration - Google Patents
Intra-articular gel for tissue and cartilage regeneration Download PDFInfo
- Publication number
- WO2024080954A1 WO2024080954A1 PCT/TR2023/050964 TR2023050964W WO2024080954A1 WO 2024080954 A1 WO2024080954 A1 WO 2024080954A1 TR 2023050964 W TR2023050964 W TR 2023050964W WO 2024080954 A1 WO2024080954 A1 WO 2024080954A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- articular
- intra
- gel
- formulation
- glycine
- Prior art date
Links
- 210000001519 tissue Anatomy 0.000 title claims abstract description 16
- 230000003848 cartilage regeneration Effects 0.000 title abstract description 7
- 230000017423 tissue regeneration Effects 0.000 title abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 103
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 74
- 238000009472 formulation Methods 0.000 claims abstract description 64
- 239000004471 Glycine Substances 0.000 claims abstract description 36
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims abstract description 35
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract description 33
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 32
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 29
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 29
- 150000001413 amino acids Chemical class 0.000 claims abstract description 8
- 229960002429 proline Drugs 0.000 claims description 34
- 201000008482 osteoarthritis Diseases 0.000 claims description 33
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 239000008215 water for injection Substances 0.000 claims description 30
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 26
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 25
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 25
- 210000000845 cartilage Anatomy 0.000 claims description 17
- 239000011780 sodium chloride Substances 0.000 claims description 16
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 15
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 14
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 14
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 13
- 230000007850 degeneration Effects 0.000 claims description 12
- 229940024606 amino acid Drugs 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 4
- 229930182821 L-proline Natural products 0.000 claims description 2
- 239000012530 fluid Substances 0.000 abstract description 5
- 210000001179 synovial fluid Anatomy 0.000 description 11
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 7
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229920002674 hyaluronan Polymers 0.000 description 5
- 229940014041 hyaluronate Drugs 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920001287 Chondroitin sulfate Polymers 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940059329 chondroitin sulfate Drugs 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 206010060968 Arthritis infective Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010024604 Lipoatrophy Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
- 229940099552 hyaluronan Drugs 0.000 description 2
- 210000005067 joint tissue Anatomy 0.000 description 2
- 230000001050 lubricating effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- KQJSQWZMSAGSHN-UHFFFAOYSA-N (9beta,13alpha,14beta,20alpha)-3-hydroxy-9,13-dimethyl-2-oxo-24,25,26-trinoroleana-1(10),3,5,7-tetraen-29-oic acid Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(O)=C2C KQJSQWZMSAGSHN-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- AQKDBFWJOPNOKZ-UHFFFAOYSA-N Celastrol Natural products CC12CCC3(C)C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C2=CC=C2C1=CC(=O)C(=O)C2C AQKDBFWJOPNOKZ-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- KQJSQWZMSAGSHN-JJWQIEBTSA-N celastrol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@](C)(C(O)=O)CC[C@]1(C)CC[C@]2(C)C4=CC=C1C3=CC(=O)C(O)=C1C KQJSQWZMSAGSHN-JJWQIEBTSA-N 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000003011 chondroprotective effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 150000003334 secondary amides Chemical group 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
Definitions
- the present invention relates to an intra-articular gel composition which provides tissue and cartilage regeneration and to a gel formulation wherein the gel composition is presented in a carrier fluid. More particularly, the present invention relates to a composition and a formulation of an intra-articular gel with greatly improved pH stability.
- Osteoarthritis is a degenerative joint disease thataffects the bone and soft tissues of the joint. Osteoarthritis, which belongs to the group of rheumatic diseases, is characterized as a type of arthritis (joint inflammation/arthritis) within this category. Osteoarthritis (OA) is a chronic and progressive disease that causes significant pain and difficulty in movement in patients.
- Cartilage is a hard and slippery tissue that allows almost frictionless joint movement with the help of synovial fluid. Osteoarthritis is caused by the wear of the cartilage that acts as a shock absorber at the ends of the bones in the joints. In other words, in patients with osteoarthritis, wear and tear of the cartilage occurs and the cartilage tissue deteriorates over time. This leads to changes in the bone structure and degeneration of the connective tissues that hold the joint together and connect the muscles to the bone. In addition, inflammation of the joint capsule occurs.
- Synovial fluid is a lubricating substance secreted by the synovial membrane that surrounds the area where two bones meetin the joints. This lubricating substance allows the jointto move easily.
- the pH of the synovial fluid is alkaline and ranges from about 7.3 to 7.6.
- the pH of the synovial fluid moves towards the acidic range and can sometimes drop as low as 6.0 (Jin, T., et al. (2020).
- Intraarticular injections for the treatment of osteoarthritis focus on the clinical use of hyaluronic acid. Drugs in R&D, 11(1), 13-27).
- intra-articular fluid supplements commonly used in the early stage of cartilage degeneration include; mixtures comprising hyaluronic acid-sodium, hyaluronic acid- sodium/chondroitin sulfate or hyaluronic acid-sodium/chondroitin sulfate/N-acetylglucosamine.
- Hyaluronate (also known as hyaluronic acid and hyaluronan) is a high molecular mass polysaccharide found naturally in the extracellular space of higher animals, especially in soft connective tissues. It is a linear polymer consisting of repeating monomers of n-acetyl glucosamine and glucuronic acid. Hyaluronate plays an important role in protecting the synovial joint by contributing to joint lubrication by buffering load transfer across articular surfaces (Schiavinato, A., Finesso, M., Cortivo, R., & Abatangelo, G. (2002). Comparison of the effects of intraarticular injections of Hyaluronan and its chemically cross-linked derivative (Hylan G-F20) in normal rabbit knee joints. Clinical and experimental rheumatology, 20(4), 445-454).
- hyaluronate which is used for tissue regeneration in the treatment of osteoarthritis, is its sodium salt, sodium hyaluronate.
- Sodium hyaluronate is injected into the joint as part of osteoarthritis treatment to act as both a shock absorber and lubricant for the joint.
- Sodium hyaluronate has the following chemical structure:
- N- Acetyl glucosamine (GlcNAc), whose chemical structure is given below, is an amide derivative of the monosaccharide glucose. It is a secondary amide between glucosamine and acetic acid.
- GlcNAc N- Acetyl glucosamine
- EP2886104A1 discloses an intra-articular gel formulation comprising sodium hyaluronate, N- acetyl glucosamine and chondroitin sulfate for the treatment of osteoarthritis.
- Glycine has the chemical formula NH2-CH2-COOH and is the simplest stable amino acid. Glycine can be used in pharmaceutical formulations as a buffering agent, wetting agent, bulking agent, dietary supplement, tablet disintegrant and freeze-drying agent (Raymond C Rowe, Paul J, Sheskey & Marian E, Quinn (2009). Handbook of Pharmaceutical Excipients, 6th ed. RPS Publishing).
- EP3544616A1 discloses that proline, another amino acid, is comprised in the formulation in order to stabilize the lyophilized formulation containing dalbavansin.
- the amino acids glycine and proline are important building blocks for collagen synthesis in joints. Osteoarthritis patients require large amounts of glycine, proline and lysine to restore normal levels of collagen synthesis, which is reduced due to osteoarthritis (de Paz-Lugo, P., et al. (2016), High glycine concentration increases collagen synthesis by articular chondrocytes in vitro: acute glycine deficiency could be an important cause of osteoarthritis. Amino acids, 50(10), 1357-1365).
- EP1713464A2 relates to a method for increasing the flexibility of cartilage in an animal in need of such increase.
- the method involves administering to a mammal an effective amount of at least one of glycine and proline in order to increase cartilage flexibility.
- EP2515897B1 relates to the use of an intra-articular gel containing a combination of glycine and proline in the treatment of osteoarthritis.
- the combination may also comprise a natural or synthetic viscosity-controlling polymer.
- intra-articular gel formulations for the treatment of osteoarthritis are known in the relevant field.
- the present invention provides an intra-articular gel formulation having a stable pH that is compatible with the pH range of the synovial fluid observed in osteoarthritis patients. Said formulation increases patient compliance by preventing irritation and pain that may occur during and following administration.
- the present invention provides a composition and a formulation with high stability and thus extended shelflife. The compositions and formulations of the present invention are therefore advantageous in that they provide pH-stable products that maintain the efficacy and stability of the active ingredient and minimize the side effects.
- the invention provides an intra-articular gel composition, wherein said composition comprises the following components by weight:
- the intra-articular gel composition of the invention preferably comprises the following components by weight:
- the intra-articular gel composition of the invention comprises the following components by weight:
- the intra-articular gel composition of the invention may further be mixed with a carrier fluid, more preferably with water for injection, to form suitable formulations.
- the intra-articular gel formulation of the invention preferably comprises between 5 mg and 40 mg of sodium hyaluronate in 1 ml of water. More preferably, the amount of sodium hyaluronate is 15 mg.
- amino acids proline and glycine comprised in the intra-articular gel composition or formulation of the invention are preferably in the L configuration.
- the invention provides the intra-articular gel formulation of the invention for use in the prevention and/or treatment of tissue and/or cartilage degeneration in humans or animals.
- Said tissue and/or cartilage degeneration is preferably tissue and/or cartilage degeneration due to osteoarthritis.
- the present invention relates to an intra-articular gel formulation with high pH stability.
- Said formulation comprises NaH 2 PO 4 (monosodium phosphate), Na 2 HPO 4 (disodium phosphate), NaCl (sodium chloride), N-acetyl-D- glucosamine, glycine, proline and sodium hyaluronate.
- the intra- articular gel formulation of the invention is effective in the prevention and/or treatment of cartilage degeneration, in particular in the treatment of osteoarthritis.
- the present invention provides an intra-articular gel formulation, said formulation comprises the following components by weight:
- the formulation of the invention preferably comprises said components in the following percentages by weight:
- the formulation of the invention more preferably comprises said components in the following percentages by weight:
- composition or formulation according to the present invention is intended to provide a product with high pH stability.
- Inventors of the present application have realized that combining the components of the composition in the percentages given above allows to obtain a product with high pH stability, as will be described in more detail below.
- composition of the present invention may comprise NaH 2 P04, Na2HP04, NaCl, N- acetyl-D-glucosamine, glycine, proline and sodium hyaluronate in any percentage within the above-mentioned weight percentage ranges, as to add up to 100%.
- the intraarticular gel composition of the invention may comprise, by weight:
- composition of the present invention may further be mixed with a carrier fluid, more preferably with water for injection, to obtain formulations of the invention.
- a carrier fluid more preferably with water for injection
- the amount of water for injection in which the components of the formulation are dissolved is preferably 1 ml.
- amino acids proline and glycine comprised in the intra-articular gel composition of the invention are preferably in the L configuration.
- the invention provides the intra-articular gel composition or formulation according to the invention for use in the prevention and/or treatment of tissue and/or cartilage degeneration in humans or animals.
- Said tissue and/or cartilage degeneration is preferably tissue and/or cartilage degeneration due to osteoarthritis.
- the molecular weight of the sodium hyaluronate comprised in the intra-articular gel composition of the invention is preferably in the range of 800 kDa to 3 MDa, more preferably in the range of 1 MDa to 2.5 MDa.
- the molecular weight of the sodium hyaluronate comprised in the formulation of the invention may be, for example, 800 kDa, 1 MDa, 1.5 MDa, 2 MDa, 2.5 MDa or 3 MDa.
- the amount of sodium hyaluronate in 1 ml of the intra-articular gel formulation of the invention is preferably in the range of 5 mg to 40 mg, more preferably in the range of 7.5 mg to 30 mg. More specifically, the amount of sodium hyaluronate in 1 ml of water for injection is in the range of 10 mg to 20 mg.
- the amount of sodium hyaluronate in 1 ml of water for injection may be, for example, 10 mg, 13 mg, 15 mg, 18 mg or 20 mg.
- the amount of sodium hyaluronate in 1 ml of water for injection is most preferably 15 mg.
- the amount of glycine in 1 ml of the intra-articular gel formulation of the invention is preferably in the range of 1 mg to 15 mg, more preferably in the range of 2.25 mg to 12.5 mg. More specifically, the amount of glycine in 1 ml of water for injection is in the range of 5 mg to 10 mg.
- the amount of glycine in 1 ml of water for injection may be, for example, 5 mg, 6 mg, 7.5 mg, 9 mg or 10 mg.
- the amount of glycine in 1 ml of water for injection is most preferably 7.5 mg.
- Said glycine is preferably L-glycine.
- the amount of proline in 1 ml of the intra-articular gel formulation of the invention is preferably in the range of 1 mg to 12.5 mg, more preferably in the range of
- the amount of proline in 1 ml of water for injection is in the range of 3.75 mg to 6.5 mg.
- the amount of proline in 1 ml of water for injection may be, for example, 3.75 mg, 4 mg, 4.5 mg, 5 mg, 5.5 mg, 6 mg or 6.5 mg.
- the amount of proline in 1 ml of water for injection is most preferably 5 mg.
- Said proline is preferably L-proline.
- the amount of N-acetyl-D-glucosamine in 1 ml of the intra-articular gel formulation of the invention is preferably in the range of 5 mg to 30 mg, more preferably in the range of 7.5 mg to 25 mg. More specifically, the amount of N-acetyl-D- glucosamine in 1 ml of water for injection is in the range of 10 mg to 20 mg.
- the amount of N- acetyl-D-glucosamine in 1 ml of water for injection may be, for example, 10 mg, 12.5 mg, 15 mg,
- N-acetyl-D-glucosamine 17.5 mg.
- the amount of N-acetyl-D-glucosamine in 1 ml of water for injection is most preferably 15 mg.
- Said N-acetyl-D-glucosamine may be synthetic.
- the amount of NalkPC (monosodium phosphate) in 1 ml of the intra-articular gel formulation of the invention is preferably in the range of 0.25 mg to 0.75 mg, more preferably in the range of 0.35 mg to 0.60 mg.
- the amount of NalkPC in 1 ml of water for injection is most preferably 0.45 mg.
- the amount of Na2HPC>4 (disodium phosphate) in 1 ml of the intra-articular gel formulation of the invention is preferably in the range of 0.5 mg to 5 mg, more preferably in the range of 1 mg to 3.5 mg.
- the amount of Na2HPC>4 in 1 ml of water for injection is most preferably 2 mg.
- the amount of NaCl (sodium chloride) in 1 ml of the intra-articular gel formulation of the invention is preferably in the range of 2.5 mg to 7.5 mg, more preferably in the range of 3.5 mg to 6 mg.
- the amount of Naf ⁇ PC in 1 ml of water for injection is most preferably 4.5 mg.
- the formulation according to the invention may comprise any combination of amounts of the components of the formulation corresponding to the ranges of amounts given above.
- the inventors have found that combining the components of the formulation in these ranges of amounts advantageously allows for both the high efficacy of the active ingredient and the high pH stability of the formulation.
- Example 1 Intra-Articular Gel Formulation in 1 ml of Water for Injection
- the intra-articular gel formulation according to a preferred embodiment of the present invention is given in Table 1 below.
- the gel of Example 1 is an intra-articular matrix gel for the treatment of osteoarthritis, degenerative joint diseases and degenerative meniscal tears due to synovial fluid deficiency and for the promotion of cartilage regeneration. Said gel is administered into the joint by injection. pH Stability Studies
- Table 2 shows that the pH values of the gel formulations without glycine and proline were measured in the range of 6.92 to 7.28 before sterilization, wherein the formulations containing 10 mg/ml, 18 mg/ml and 20 mg/ml Hyaluronate were around 7.0. However, after autoclaving at 121°C for 15 minutes, a major deviation was observed in pH values for all concentrations and pH values even exceeded 7.4 for some concentrations.
- Table 3 shows that the pH values of the gel formulations containing glycine and proline proved a high stability around pH 7.0 both before and after sterilization.
- the gel formulation samples of the invention maintain their pH stability to a great extent before and after sterilization (autoclave) in case they contain glycine and proline.
- intra-articular compositions with a pH of 7.4 or higher may cause various adverse effects such as post-injection pain, flare-ups, skin pigment changes, fat atrophy and joint infection by activating the inflammatory enzymes, and adversely affect drug stabilization (lannitti, T., Lodi, D., & Palmieri, B. (2011).
- Intra-articular injections for the treatment of osteoarthritis focus on the clinical use of hyaluronic acid. Drugs in R&D, 11(1), 13-27). Therefore, the formulations of the present invention, which have a highly stable pH value due to the glycine and proline components and their specific percentages in the formulation, increase patient compliance and allow the active ingredient to be injected with maximum efficiency due to their pH stability.
- the intra-articular gel formulation of the present invention is stable due to its components and their specific weight percentages, the pH level of the formulation is substantially maintained around 7.0 and thus the formulation can be safely injected into the synovial fluid without causing irritation or pain to the patient.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides an intra-articular gel composition that promotes tissue and cartilage regeneration and a gel formulation in which the gel composition is provided in a carrier fluid. Said composition and formulation comprises sodium hyaluronate as well as the amino acids glycine and proline.
Description
INTRA- ARTICULAR GEL FOR TISSUE AND CARTILAGE REGENERATION
Technical Field
The present invention relates to an intra-articular gel composition which provides tissue and cartilage regeneration and to a gel formulation wherein the gel composition is presented in a carrier fluid. More particularly, the present invention relates to a composition and a formulation of an intra-articular gel with greatly improved pH stability.
Background of the Invention
Osteoarthritis (OA) is a degenerative joint disease thataffects the bone and soft tissues of the joint. Osteoarthritis, which belongs to the group of rheumatic diseases, is characterized as a type of arthritis (joint inflammation/arthritis) within this category. Osteoarthritis (OA) is a chronic and progressive disease that causes significant pain and difficulty in movement in patients.
Cartilage is a hard and slippery tissue that allows almost frictionless joint movement with the help of synovial fluid. Osteoarthritis is caused by the wear of the cartilage that acts as a shock absorber at the ends of the bones in the joints. In other words, in patients with osteoarthritis, wear and tear of the cartilage occurs and the cartilage tissue deteriorates over time. This leads to changes in the bone structure and degeneration of the connective tissues that hold the joint together and connect the muscles to the bone. In addition, inflammation of the joint capsule occurs.
Synovial fluid is a lubricating substance secreted by the synovial membrane that surrounds the area where two bones meetin the joints. This lubricating substance allows the jointto move easily. Under normal physiological conditions, the pH of the synovial fluid is alkaline and ranges from about 7.3 to 7.6. However, in patients with osteoarthritis, due to the accumulation of inflammatory metabolic products in and around the joint tissue, the pH of the synovial fluid moves towards the acidic range and can sometimes drop as low as 6.0 (Jin, T., et al. (2020). Intra-articular delivery of celastrol by hollow mesoporous silica nanoparticles for pH-sensitive anti-inflammatory therapy against knee osteoarthritis. J Nanobiotechnol 18, 94).
In the treatment of osteoarthritis, patients may experience joint tissue irritation and/or pain in the case the pH of therapeutic agents/compositions for the tissue and cartilage regeneration which are suitable for injection into the joint cavity differs significantly from the pH of the synovial fluid. In addition, the pH of therapeutic compositions for intra-articular administration is compatible with the low pH values in osteoarthritis patients, making it possible to maintain the
efficacy and stability of the active ingredient in the composition also within the joint A review of intra-articular injections for the treatment of osteoarthritis suggests that various adverse effects such as pain, flare-ups, skin pigment changes, fat atrophy and joint infection may occur after intraarticular injection; and that compositions with a pH value of 7.4 or lower may stabilize the drug without activating inflammatory enzymes (lannitti, T., Lodi, D., & Palmieri, B. (2011). Intraarticular injections for the treatment of osteoarthritis: focus on the clinical use of hyaluronic acid. Drugs in R&D, 11(1), 13-27). In light of this information, it can be seen that it is important in the relevant technical field to keep the pH values of the formulations for intra-articular administration stable so that they are compatible with the pH values observed in the synovial fluids of osteoarthritis patients (e.g. around pH 7.0), which are low compared to the pH values observed in the synovial fluids of healthy people.
Examples of intra-articular fluid supplements commonly used in the early stage of cartilage degeneration include; mixtures comprising hyaluronic acid-sodium, hyaluronic acid- sodium/chondroitin sulfate or hyaluronic acid-sodium/chondroitin sulfate/N-acetylglucosamine.
Hyaluronate (also known as hyaluronic acid and hyaluronan) is a high molecular mass polysaccharide found naturally in the extracellular space of higher animals, especially in soft connective tissues. It is a linear polymer consisting of repeating monomers of n-acetyl glucosamine and glucuronic acid. Hyaluronate plays an important role in protecting the synovial joint by contributing to joint lubrication by buffering load transfer across articular surfaces (Schiavinato, A., Finesso, M., Cortivo, R., & Abatangelo, G. (2002). Comparison of the effects of intraarticular injections of Hyaluronan and its chemically cross-linked derivative (Hylan G-F20) in normal rabbit knee joints. Clinical and experimental rheumatology, 20(4), 445-454).
The most widely used form of hyaluronate, which is used for tissue regeneration in the treatment of osteoarthritis, is its sodium salt, sodium hyaluronate. Sodium hyaluronate is injected into the joint as part of osteoarthritis treatment to act as both a shock absorber and lubricant for the joint. By increasing the viscosity of the synovial fluid, it helps to lubricate, cushion and reduce pain in the joint Sodium hyaluronate has the following chemical structure:
Sodium hyaluronate
N- Acetyl glucosamine (GlcNAc), whose chemical structure is given below, is an amide derivative of the monosaccharide glucose. It is a secondary amide between glucosamine and acetic acid. Studies on mice by AR. Shikhman and colleagues have shown that N-acetyl-D-glucosamine plays an important role in the production of cartilage matrix components (Shikhman, A. R., et al. (2005). Chondroprotective activity of N-acetylglucosamine in rabbits with experimental osteoarthritis. Annals of the rheumatic diseases, 64(1 ), 89-94).
N- Acetylglucosamine
EP2886104A1 discloses an intra-articular gel formulation comprising sodium hyaluronate, N- acetyl glucosamine and chondroitin sulfate for the treatment of osteoarthritis.
Glycine has the chemical formula NH2-CH2-COOH and is the simplest stable amino acid. Glycine can be used in pharmaceutical formulations as a buffering agent, wetting agent, bulking agent, dietary supplement, tablet disintegrant and freeze-drying agent (Raymond C Rowe, Paul J, Sheskey & Marian E, Quinn (2009). Handbook of Pharmaceutical Excipients, 6th ed. RPS Publishing).
EP3544616A1 discloses that proline, another amino acid, is comprised in the formulation in order to stabilize the lyophilized formulation containing dalbavansin.
In addition to their use as excipients, the amino acids glycine and proline are important building blocks for collagen synthesis in joints. Osteoarthritis patients require large amounts of glycine, proline and lysine to restore normal levels of collagen synthesis, which is reduced due to osteoarthritis (de Paz-Lugo, P., et al. (2018), High glycine concentration increases collagen synthesis
by articular chondrocytes in vitro: acute glycine deficiency could be an important cause of osteoarthritis. Amino acids, 50(10), 1357-1365).
EP1713464A2 relates to a method for increasing the flexibility of cartilage in an animal in need of such increase. The method involves administering to a mammal an effective amount of at least one of glycine and proline in order to increase cartilage flexibility.
EP2515897B1 relates to the use of an intra-articular gel containing a combination of glycine and proline in the treatment of osteoarthritis. The combination may also comprise a natural or synthetic viscosity-controlling polymer.
As can be seen, intra-articular gel formulations for the treatment of osteoarthritis are known in the relevant field. However, there is still a need for pH-stable intra-articular gel formulations for the treatment of tissue and cartilage regeneration in the relevant technical field. For this purpose, the present invention provides an intra-articular gel formulation having a stable pH that is compatible with the pH range of the synovial fluid observed in osteoarthritis patients. Said formulation increases patient compliance by preventing irritation and pain that may occur during and following administration. Furthermore, the present invention provides a composition and a formulation with high stability and thus extended shelflife. The compositions and formulations of the present invention are therefore advantageous in that they provide pH-stable products that maintain the efficacy and stability of the active ingredient and minimize the side effects.
Summary of the Invention
In one aspect, the invention provides an intra-articular gel composition, wherein said composition comprises the following components by weight:
- 0.1% to 2% NaH2PO4,
- 1% to 8% Na2HPO4,
- 2.5% to 15% NaCl,
- 20% to 40% N-acetyl-D- glucosamine,
- 7.5 % to 22.5 % glycine,
- 3.5% to 20% proline, and
- 15% to 45% sodium hyaluronate.
The intra-articular gel composition of the invention preferably comprises the following components by weight:
- 0.25% to 1.75% NaH2PO4,
- 1.5% to 6% Na2HPO4,
- 3.5% to 12.5% NaCl,
- 22.5% to 37.5% N-acetyl-D- glucosamine,
- 10 % to 20 % glycine,
- 5% to 15% proline, and
- 20% to 40% sodium hyaluronate.
In a further preferred embodiment of the invention, the intra-articular gel composition of the invention comprises the following components by weight:
- 0.5% to 1.5% NaH2PO4,
- 2% to 5% Na2HPO4,
- 5% to 10% NaCl,
- 25% to 35% N-acetyl-D-glucosamine,
- 12.5 % to 17.5 % glycine,
- 7.5% to 12.5% proline, and
- 25 % to 35 % sodium hyaluronate.
The intra-articular gel composition of the invention may further be mixed with a carrier fluid, more preferably with water for injection, to form suitable formulations.
The intra-articular gel formulation of the invention preferably comprises between 5 mg and 40 mg of sodium hyaluronate in 1 ml of water. More preferably, the amount of sodium hyaluronate is 15 mg.
The amino acids proline and glycine comprised in the intra-articular gel composition or formulation of the invention are preferably in the L configuration.
In another aspect, the invention provides the intra-articular gel formulation of the invention for use in the prevention and/or treatment of tissue and/or cartilage degeneration in humans or animals. Said tissue and/or cartilage degeneration is preferably tissue and/or cartilage degeneration due to osteoarthritis.
Detailed Description of the Invention
The present invention relates to an intra-articular gel formulation with high pH stability. Said formulation comprises NaH2PO4 (monosodium phosphate), Na2HPO4 (disodium phosphate), NaCl (sodium chloride), N-acetyl-D- glucosamine, glycine, proline and sodium hyaluronate. The intra-
articular gel formulation of the invention is effective in the prevention and/or treatment of cartilage degeneration, in particular in the treatment of osteoarthritis.
Accordingly, in one aspect, the present invention provides an intra-articular gel formulation, said formulation comprises the following components by weight:
- 0.1% to 2% NaH2PO4,
- 1% to 8% Na2HPO4,
- 2.5% to 15% NaCl,
- 20% to 40% N-acetyl-D- glucosamine,
- 7.5 % to 22.5 % glycine,
- 3.5% to 20% proline, and
- 15% to 45% sodium hyaluronate.
The formulation of the invention preferably comprises said components in the following percentages by weight:
- 0.25% to 1.75% NaH2PO4,
- 1.5% to 6% Na2HPO4,
- 3.5% to 12.5% NaCl,
- 22.5% to 37.5% N-acetyl-D- glucosamine,
- 10 % to 20 % glycine,
- 5% to 15% proline, and
- 20% to 40% sodium hyaluronate.
The formulation of the invention more preferably comprises said components in the following percentages by weight:
- 0.5% to 1.5% NaH2PO4,
- 2% to 5% Na2HPO4,
- 5% to 10% NaCl,
- 25% to 35% N-acetyl-D-glucosamine,
- 12.5% to 17.5% glycine,
- 7.5% to 12.5% proline, and
- 25% to 35% sodium hyaluronate.
The composition or formulation according to the present invention is intended to provide a product with high pH stability. Inventors of the present application have realized that combining
the components of the composition in the percentages given above allows to obtain a product with high pH stability, as will be described in more detail below.
Accordingly, the composition of the present invention may comprise NaH2P04, Na2HP04, NaCl, N- acetyl-D-glucosamine, glycine, proline and sodium hyaluronate in any percentage within the above-mentioned weight percentage ranges, as to add up to 100%. For example, the intraarticular gel composition of the invention may comprise, by weight:
- 2% NaH2PO4,
- 4% Na2HPO4,
- 7% NaCl,
- 30% N-acetyl-D-glucosamine,
- 15% glycine,
- 10% proline, and
- 32% sodium hyaluronate.
The composition of the present invention may further be mixed with a carrier fluid, more preferably with water for injection, to obtain formulations of the invention. The amount of water for injection in which the components of the formulation are dissolved is preferably 1 ml.
The amino acids proline and glycine comprised in the intra-articular gel composition of the invention are preferably in the L configuration.
In another aspect, the invention provides the intra-articular gel composition or formulation according to the invention for use in the prevention and/or treatment of tissue and/or cartilage degeneration in humans or animals. Said tissue and/or cartilage degeneration is preferably tissue and/or cartilage degeneration due to osteoarthritis.
The molecular weight of the sodium hyaluronate comprised in the intra-articular gel composition of the invention is preferably in the range of 800 kDa to 3 MDa, more preferably in the range of 1 MDa to 2.5 MDa. The molecular weight of the sodium hyaluronate comprised in the formulation of the invention may be, for example, 800 kDa, 1 MDa, 1.5 MDa, 2 MDa, 2.5 MDa or 3 MDa.
The amount of sodium hyaluronate in 1 ml of the intra-articular gel formulation of the invention (i.e. in 1 ml of water for injection) is preferably in the range of 5 mg to 40 mg, more preferably in the range of 7.5 mg to 30 mg. More specifically, the amount of sodium hyaluronate in 1 ml of water for injection is in the range of 10 mg to 20 mg. The amount of sodium hyaluronate in 1 ml of water
for injection may be, for example, 10 mg, 13 mg, 15 mg, 18 mg or 20 mg. The amount of sodium hyaluronate in 1 ml of water for injection is most preferably 15 mg.
The amount of glycine in 1 ml of the intra-articular gel formulation of the invention (i.e. in 1 ml of water for injection) is preferably in the range of 1 mg to 15 mg, more preferably in the range of 2.25 mg to 12.5 mg. More specifically, the amount of glycine in 1 ml of water for injection is in the range of 5 mg to 10 mg. The amount of glycine in 1 ml of water for injection may be, for example, 5 mg, 6 mg, 7.5 mg, 9 mg or 10 mg. The amount of glycine in 1 ml of water for injection is most preferably 7.5 mg. Said glycine is preferably L-glycine.
The amount of proline in 1 ml of the intra-articular gel formulation of the invention (i.e. in 1 ml of water for injection) is preferably in the range of 1 mg to 12.5 mg, more preferably in the range of
2.5 mg to 7.5 mg. More specifically, the amount of proline in 1 ml of water for injection is in the range of 3.75 mg to 6.5 mg. The amount of proline in 1 ml of water for injection may be, for example, 3.75 mg, 4 mg, 4.5 mg, 5 mg, 5.5 mg, 6 mg or 6.5 mg. The amount of proline in 1 ml of water for injection is most preferably 5 mg. Said proline is preferably L-proline.
The amount of N-acetyl-D-glucosamine in 1 ml of the intra-articular gel formulation of the invention (i.e. in 1 ml of water for injection) is preferably in the range of 5 mg to 30 mg, more preferably in the range of 7.5 mg to 25 mg. More specifically, the amount of N-acetyl-D- glucosamine in 1 ml of water for injection is in the range of 10 mg to 20 mg. The amount of N- acetyl-D-glucosamine in 1 ml of water for injection may be, for example, 10 mg, 12.5 mg, 15 mg,
17.5 mg. The amount of N-acetyl-D-glucosamine in 1 ml of water for injection is most preferably 15 mg. Said N-acetyl-D-glucosamine may be synthetic.
The amount of NalkPC (monosodium phosphate) in 1 ml of the intra-articular gel formulation of the invention (i.e. in 1 ml of water for injection) is preferably in the range of 0.25 mg to 0.75 mg, more preferably in the range of 0.35 mg to 0.60 mg. The amount of NalkPC in 1 ml of water for injection is most preferably 0.45 mg.
The amount of Na2HPC>4 (disodium phosphate) in 1 ml of the intra-articular gel formulation of the invention (i.e. in 1 ml of water for injection) is preferably in the range of 0.5 mg to 5 mg, more preferably in the range of 1 mg to 3.5 mg. The amount of Na2HPC>4 in 1 ml of water for injection is most preferably 2 mg.
The amount of NaCl (sodium chloride) in 1 ml of the intra-articular gel formulation of the invention (i.e. in 1 ml of water for injection) is preferably in the range of 2.5 mg to 7.5 mg, more
preferably in the range of 3.5 mg to 6 mg. The amount of Naf^PC in 1 ml of water for injection is most preferably 4.5 mg.
The formulation according to the invention may comprise any combination of amounts of the components of the formulation corresponding to the ranges of amounts given above. The inventors have found that combining the components of the formulation in these ranges of amounts advantageously allows for both the high efficacy of the active ingredient and the high pH stability of the formulation.
Formulation
Example 1: Intra-Articular Gel Formulation in 1 ml of Water for Injection
The intra-articular gel formulation according to a preferred embodiment of the present invention is given in Table 1 below.
Table 1: Intra-Articular Gel Formulation in 1 ml of Water for Injection
The gel of Example 1 is an intra-articular matrix gel for the treatment of osteoarthritis, degenerative joint diseases and degenerative meniscal tears due to synovial fluid deficiency and for the promotion of cartilage regeneration. Said gel is administered into the joint by injection. pH Stability Studies
As explained in detail above, it is essential to keep intra-articular gel formulations stable at a preferred pH value. As a result of their observations, the inventors realized that the gel of the invention, which is provided for administering to osteoarthritis patients, should be maintained stable around pH 7.0. For the intra-articular gel formulations according to the invention comprising Hyaluronate at the concentrations indicated in Table 2 and Table 3 below (10 mg/ml, 13 mg/ml, 15 mg/ml, 18 mg/ml and 20 mg/ml), pH stability was evaluated under two different
conditions: 1) pH Values for the Gel Samples without Glycine and Proline (Table 2) and 2) pH Values for the Gel Samples with Glycine and Proline (Table 3).
Table 2: pH Values of Glycine-Free and Proline-Free Gel Samples Before and After Sterilization
Table 3: pH Values of Glycine and Proline Containing Gel Samples Before and After Sterilization
Table 2 shows that the pH values of the gel formulations without glycine and proline were measured in the range of 6.92 to 7.28 before sterilization, wherein the formulations containing 10 mg/ml, 18 mg/ml and 20 mg/ml Hyaluronate were around 7.0. However, after autoclaving at 121°C for 15 minutes, a major deviation was observed in pH values for all concentrations and pH values even exceeded 7.4 for some concentrations.
Table 3 shows that the pH values of the gel formulations containing glycine and proline proved a high stability around pH 7.0 both before and after sterilization.
In the light of this information, it can be seen that the gel formulation samples of the invention maintain their pH stability to a great extent before and after sterilization (autoclave) in case they contain glycine and proline. It is known in the relevant art that intra-articular compositions with a pH of 7.4 or higher may cause various adverse effects such as post-injection pain, flare-ups, skin pigment changes, fat atrophy and joint infection by activating the inflammatory enzymes, and adversely affect drug stabilization (lannitti, T., Lodi, D., & Palmieri, B. (2011). Intra-articular injections for the treatment of osteoarthritis: focus on the clinical use of hyaluronic acid. Drugs in R&D, 11(1), 13-27). Therefore, the formulations of the present invention, which have a highly stable pH value due to the glycine and proline components and their specific percentages in the formulation, increase patient compliance and allow the active ingredient to be injected with maximum efficiency due to their pH stability.
The intra-articular gel formulation of the present invention is stable due to its components and their specific weight percentages, the pH level of the formulation is substantially maintained around 7.0 and thus the formulation can be safely injected into the synovial fluid without causing irritation or pain to the patient.
Claims
1. An intra-articular gel composition, wherein the composition comprises the following components by weight:
- 0.1% to 2% NaH2PO4,
- 1% to 8% Na2HPO4,
- 2.5% to 15% NaCl,
- 20% to 40% N-acetyl-D- glucosamine,
- 7.5 % to 22.5 % glycine,
- 3.5% to 20% proline, and
- 15% to 45% sodium hyaluronate.
2. The intra-articular gel composition according to claim 1, wherein the composition comprises the following components by weight:
- 0.25% to 1.75% NaH2PO4,
- 1.5% to 6% Na2HPO4,
- 3.5% to 12.5% NaCl,
- 22.5% to 37.5% N-acetyl-D- glucosamine,
- 10 % to 20 % glycine,
- 5% to 15% proline, and
- 20% to 40% sodium hyaluronate.
3. The intra-articular gel composition according to claim 2, wherein the composition comprises the following components by weight:
- 0.5% to 1.5% NaH2PO4,
- 2% to 5% Na2HPO4,
- 5% to 10% NaCl,
- 25% to 35% N-acetyl-D-glucosamine,
- 12.5 % to 17.5 % glycine,
- 7.5% to 12.5% proline, and
- 25% to 35% sodium hyaluronate.
4. The intra-articular gel composition according to any one of claims 1 to 3, wherein the amino acids glycine and proline comprised in the composition are in the L configuration.
5. An intra-articular gel formulation comprising the intra-articular gel composition according to any one of the preceding claims and water for injection.
6. The intra-articular gel formulation according to claim 5, wherein the formulation comprises between 5 mg and 40 mg of sodium hyaluronate in 1 ml of water for injection.
7. The intra-articular gel formulation according to claim 6, wherein the formulation comprises 15 mg sodium hyaluronate in 1 ml water for injection.
8. The intra-articular gel formulation according to claim 5, wherein the formulation comprises the following components by weight::
Component Amount (mg)
NaH2PO4 0.45
Na2HPO4 2.00
NaCl 4.50
N-Acetyl-D-glucosamine 15.00
L-glycine 7.50
L-proline 5.00
Sodium hyaluronate 15.00
9. The intra-articular gel composition according to any one of claims 1 to 4 or the intra-articular gel formulation according to any one of claims 5 to 8 for use in the prevention and/or treatment of tissue and/or cartilage degeneration in humans or animals.
10. The composition or formulation for use according to claim 9, wherein said tissue and/or cartilage degeneration is tissue and/or cartilage degeneration due to osteoarthritis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2022015493 | 2022-10-11 | ||
| TR2022/015493 TR2022015493A2 (en) | 2022-10-11 | INTRA-ARTICULAR GEL FOR TISSUE AND CARTILE REGENERATION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2024080954A1 true WO2024080954A1 (en) | 2024-04-18 |
Family
ID=90669766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2023/050964 WO2024080954A1 (en) | 2022-10-11 | 2023-09-15 | Intra-articular gel for tissue and cartilage regeneration |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2024080954A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020068718A1 (en) * | 2000-10-03 | 2002-06-06 | Pierce Scott W. | Chondroprotective/restorative compositions and methods of use thereof |
| WO2004034980A2 (en) * | 2002-10-16 | 2004-04-29 | Marcum Frank D | Treatment for traumatic synovitis and damaged articular cartilage |
| US20050234012A1 (en) * | 2001-12-21 | 2005-10-20 | Jafari Masoud R | Combinations of viscoelastics for use during surgery |
-
2023
- 2023-09-15 WO PCT/TR2023/050964 patent/WO2024080954A1/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020068718A1 (en) * | 2000-10-03 | 2002-06-06 | Pierce Scott W. | Chondroprotective/restorative compositions and methods of use thereof |
| US20050234012A1 (en) * | 2001-12-21 | 2005-10-20 | Jafari Masoud R | Combinations of viscoelastics for use during surgery |
| WO2004034980A2 (en) * | 2002-10-16 | 2004-04-29 | Marcum Frank D | Treatment for traumatic synovitis and damaged articular cartilage |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210128604A1 (en) | Stabilized Glycosaminoglycan Preparations and Related Methods | |
| US6924273B2 (en) | Chondroprotective/restorative compositions and methods of use thereof | |
| KR101460815B1 (en) | Pharmaceutical agent having long-lasting effect of treating arthritic disorders | |
| JP6113424B2 (en) | Compositions and methods for the formulation of stabilized polysaccharides | |
| CA2703866C (en) | Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases | |
| US20140343012A1 (en) | Compositions and methods for treating joints | |
| US8506972B2 (en) | Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions | |
| JP2020189870A (en) | Composition and kit for treating joints | |
| EP2090307A1 (en) | Pharmaceutical composition for the treatment or prevention of osteoarticular diseases | |
| US20140038917A1 (en) | Sterile and injectable aqueous formulation for administration in the intra-articular space of an intra-articular joint | |
| CN1771986A (en) | Orally taken joint function protectant | |
| JP2011037849A (en) | Hyaluronic acid mixture used for treating and preventing peptic ulcer and duodenal ulcer | |
| EP1677806A1 (en) | Methods for treating acute and overuse sprain and strain using hyaluronic acid | |
| EA024569B1 (en) | Highly biocompatible dual thermogelling chitosan/glucosamine salt compositions | |
| AU767689B2 (en) | Compositions based on chondroitin sulphate and chitosan for preventing or treating rheumatic disorders by general administration | |
| RU2737380C2 (en) | Combined agent for intraarticular administration | |
| WO2024080954A1 (en) | Intra-articular gel for tissue and cartilage regeneration | |
| RU2008126108A (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OSTEOARTHRITIS CONTAINING CLODRONIC ACID AND HYALURONIC ACID | |
| WO2011160146A1 (en) | Pharmaceutical preparation containing dextran and sodium hyaluronate for the treatment of joint disorders | |
| US20220280555A1 (en) | Composition Comprising Hyaluronic Acid and Pluronic for Preventing or Treating Articular and Cartilage Injury | |
| TR2022015493A2 (en) | INTRA-ARTICULAR GEL FOR TISSUE AND CARTILE REGENERATION | |
| JPH11279205A (en) | Suppression of decomposition of hyaluronic acid preparations | |
| EP3334411A1 (en) | Injectable liquid composition for use in the intra-articular infiltration therapy | |
| CA2446615C (en) | Nutritional composition for the treatment of connective tissue | |
| KR20220152904A (en) | Composition for preventing or treating arthritis containing dna fraction and chondroitin sulfate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23877825 Country of ref document: EP Kind code of ref document: A1 |